Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do SciELO, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Human immunodeficiency virus type 1 Brazilian subtype B variant showed an increasing avidity of the anti-V3 antibodies over time compared to the subtype B US/European strain in São Paulo, Brazil

Texto completo
Autor(es):
Jorge Casseb ; Patricia Montanheiro ; Shirley Komninakis ; Adriana Brito ; Alberto JS Duarte
Número total de Autores: 5
Tipo de documento: Artigo Científico
Fonte: Memórias do Instituto Oswaldo Cruz; v. 99, n. 1, p. 69-71, Fev. 2004.
Resumo

The Brazilian variant of human immunodeficiency virus type 1 (HIV-1) subtype B, (serotype B"-GWGR), has a tryptophan replacing the proline in position 328 the HIV-1 envelope. A longer median time period from infection to acquired immunodeficiency syndrome (AIDS) for serotype B (B"-GWGR) infected subjects compared to the B-GPGR US/European strain was reported. In a cohort study, in São Paulo city, 10 B"-GWGR patients had a statistically significant increased avidity of the anti-V3 antibodies, from 79% ± 33% to 85% ± 75%, versus from 48% ± 59% to 32% ± 17% for the 10 B-GPGR subjects (p = 0.02). The T CD4+ cells showed a mean increase of + 0.45 cells/month for the B-GPGR subjects and for B"-GWGR the slope was + 1.24 cells/month (p = 0.06), for 62 and 55 months of follow up, respectively. RNA plasma viral load decreased from 3.98 ± 1.75 to 2.16 ± 1.54 log10 in the B"-GWGR group while B-GPGR patients showed one log10 reduction in viral load from 4.09 ± 0.38 to 3.17 ± 1.47 log10 over time (p = 0.23), with a decreasing slope of 0.0042 ± log10,/month and 0.0080 ± log10/month, for B-GPGR and B"-GWGR patients, respectively (p = 0.53). Neither group presented any AIDS defining events during the study, according to Center for Diseases Control criteria. Although the sample size is small, these results may indicate that differences in the pathogenicity of the 2 HIV-1 B serotypes which co-circulate in Brazil may be correlated to the avidity of anti-V3 antibodies. (AU)

Processo FAPESP: 99/11188-1 - Perfil de citocinas e quantificação de carga viral de DNA de HTLV-I em indivíduos infectados pelo HIV e co-infectados pelo vírus HTLV-I
Beneficiário:Jorge Simão do Rosário Casseb
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 98/00261-7 - Avaliação de anticorpos para a alça V3 do envelope do vírus da imunodeficiência humana tipo 1 (HIV-1)
Beneficiário:Shirley Cavalcante Vasconcelos
Linha de fomento: Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
Processo FAPESP: 97/11502-2 - Avaliação de anticorpos para a alça V3 do envelope do vírus da imunodeficiência humana tipo (HIV-1)
Beneficiário:Alberto José da Silva Duarte
Linha de fomento: Auxílio à Pesquisa - Regular